0.325
0.00 (0.84%)
| Previous Close | 0.322 |
| Open | 0.322 |
| Volume | 859,696 |
| Avg. Volume (3M) | 2,510,210 |
| Market Cap | 17,935,320 |
| Price / Sales | 0.950 |
| Price / Book | 3.17 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 |
| Operating Margin (TTM) | -375.94% |
| Diluted EPS (TTM) | -2.47 |
| Quarterly Revenue Growth (YOY) | 32.50% |
| Current Ratio (MRQ) | 2.28 |
| Operating Cash Flow (TTM) | -120.47 M |
| Levered Free Cash Flow (TTM) | -66.13 M |
| Return on Assets (TTM) | -57.75% |
| Return on Equity (TTM) | -2,986.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Marinus Pharmaceuticals, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.94% |
| % Held by Institutions | 83.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 4.00 (Cantor Fitzgerald, 1,130.77%) | Buy |
| Median | 2.50 (669.23%) | |
| Low | 0.500 (Jefferies, 53.85%) | Hold |
| Average | 2.25 (592.31%) | |
| Total | 3 Buy, 3 Hold | |
| Avg. Price @ Call | 0.338 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 Nov 2024 | 4.00 (1,130.77%) | Buy | 0.309 |
| 25 Oct 2024 | 4.00 (1,130.77%) | Buy | 0.405 | |
| HC Wainwright & Co. | 14 Nov 2024 | 2.00 (515.38%) | Hold | 0.309 |
| D. Boral Capital | 13 Nov 2024 | 3.00 (823.08%) | Buy | 0.302 |
| Jefferies | 25 Oct 2024 | 0.500 (53.85%) | Hold | 0.405 |
| RBC Capital | 25 Oct 2024 | 1.00 (207.69%) | Hold | 0.405 |
| EF Hutton | 24 Oct 2024 | 3.00 (823.08%) | Buy | 0.296 |
| 17 Oct 2024 | 23.00 (6,976.92%) | Buy | 1.74 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |